Medication is not a quick fix for obesity, Dr. Samuel L. Wilcox said during a "Lunch & Learn" session at the Iola Public ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular ...

Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...